News

Sage Therapeutics: A Speculative Play That Needs To Wait For A Turnaround Story
Sage Therapeutics faces challenges with a 90% value drop but shows promise with Zurzuvae for postpartum depression. Click ...
Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag
Biogen's $7.22 per share buyout offer signals confidence in Sage's commercial potential and drug pipeline. Read why SAGE ...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Connect
NEW YORK, NY / ACCESS Newswire / March 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...
Hosted on MSN11mon
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
Sage Therapeutics SAGE reported a loss of ... In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 EPShave risen from $4.12 to $4.43. Meanwhile, during the same period, EPS estimates ...